Every article about these drugs eventually arrives at the same sentence: eat more protein to protect muscle. It is repeated by clinics, by telehealth services, by supplement sellers and by news coverage, usually without a citation, and often with a gram-per-kilogram figure attached.
This page is about what is underneath it. The short answer is that the advice is plausible, widely given, and not yet tested in this population — and that the trial designed to test it posts its primary result in 2029.
What the evidence consists of
The most useful single document here is a systematic scoping review published in Obesity Reviews in June 2026, which searched five databases for studies published between January 2015 and April 2025 that combined semaglutide or tirzepatide with either a dietary intervention or a measured nutrition outcome.
It found twelve studies: ten randomised controlled trials, one non-randomised comparative study, one cross-sectional observational study. Across them, energy intake fell by 24% to 39%, and "lean tissue loss accounted for up to 40% of total weight reduction".
Two sentences from the same review describe the state of the field better than any summary could:
"Only three studies involved nutrition professionals, and systematic assessment of protein or micronutrient intake was rare."
"Despite the effectiveness of semaglutide and tirzepatide for weight loss, evidence on optimal dietary strategies is sparse."
The review's authors go on to say that high-protein, nutrient-dense diets and early dietitian involvement "should be prioritized". That is their recommendation, and it is reported here as theirs. What the same paper establishes as fact is that the trials to support it have not been run.
A narrative review published a month later reaches the same place from the surgical side, and states it without hedging: appetite suppression "may worsen inadequate protein intake and micronutrient deficiencies, increasing risks of sarcopenia, anemia, and bone disease without structured monitoring and supplementation", but "direct trial evidence for supplementation strategies in this specific population is lacking".
The trial that would answer it
There is one, it is properly designed, and it will not report for years.
LEAN-PREP, registered as NCT06885736, randomises 232 adults with obesity in four equal groups — control, resistance exercise, protein supplementation, or both — all of them beginning semaglutide or tirzepatide therapy at the Dasman Diabetes Institute in Kuwait. The protein arm targets 1.6 g per kilogram of body weight per day, through diet and protein products. Its primary outcome is not a scale reading and not a DXA number but MRI-measured quadriceps cross-sectional area, with DXA body composition, strength, physical function, liver fat and intramuscular fat as secondary outcomes.
Read from the registry on 2026-09-21: recruiting, start date 2025-08-07, primary completion date 2029-08-30, no results posted.
A registry search the same day for a protein-supplementation intervention alongside any of the three drugs by name returned exactly one record, NCT06989203, also recruiting and also with nothing posted.
So the field's position, stated plainly: the single most repeated piece of nutritional advice attached to the best-selling drug class of the decade rests on twelve studies in which protein intake was rarely measured, and the trial built to test it directly is three years from its primary result.
The 40% figure, and the denominator nobody states
"Up to 40% of the weight lost is muscle" is the number that travels. It comes from the scoping review above, and it is an upper bound across a heterogeneous set of studies rather than a typical value.
It is also a ratio, and that matters more than the heterogeneity. The denominator is total weight lost, so it moves whenever the weight loss does.
The only published study with both a high-protein lifestyle arm and the same programme plus a GLP-1 makes the problem concrete. Capristo 2018 was a three-arm pilot in 75 non-diabetic people eligible for bariatric surgery, each of whom chose their own arm — which is why it is a pilot and not evidence of causation. The lifestyle programme was a very-low-calorie diet for a month, then 12 kcal/kg/day of a high-protein, high-fat diet for eleven months, with daily walking and at least three hours of aerobic exercise a week.
| Arm | Weight lost | Lean body mass lost | Lean mass as a share of weight lost |
|---|---|---|---|
| Intensive lifestyle modification | 15 kg | 6.3 kg | 42% |
| Same programme + liraglutide 3 mg | 26 kg | 8.3 kg | 32% |
| Sleeve gastrectomy | 43 kg | 11.6 kg | 27% |
The right-hand column is ours, derived from the two published figures; the paper reports the kilograms.
Read the middle column and the drug arm did worse: 8.3 kg of lean mass against 6.3 kg. Read the right-hand column and it did better: 32% against 42%. Both are true of the same three people-groups, and they support opposite headlines. The paper's own discussion takes the proportional view and describes the liraglutide arm as "preserving lean body mass".
This is the reason a lean-mass claim in this market is usually unfalsifiable. Unless a source says whether its figure is absolute or proportional, and over what total, there is nothing to check.
What this page does not establish
It does not establish that protein does not help. An untested intervention is untested, not disproved, and the biological argument for it is reasonable.
It does not give a quantity for anyone to follow. The 1.6 g/kg/day figure above is the dose one registered trial is testing, reported as such. Nothing here is a plan, and what an individual should eat while taking one of these medicines is a matter for a clinician or a registered dietitian — the more so because the same reviews flag micronutrient inadequacy alongside protein.
It does not cover exercise programming, which is a different subject with a different audience and is written about by MuscleLedger. And it does not restate the trial diets themselves: the calorie deficit and activity minutes every protocol prescribed are on our GLP-1 diet page, and the labels' own near-silence on lean mass is examined on our muscle loss page.
One limitation of this page's own method is worth stating. The census above is of indexed literature and of one trial registry. A trial registered only in a national registry outside ClinicalTrials.gov would not appear in it, and this site has twice in the last week found exactly that pattern in other compounds.
Sources and dates
- Spreckley M, Ruggiero CF, Brown A. "Nutrition Strategies for Next-Generation Incretin Therapies: A Systematic Scoping Review of the Current Evidence." Obes Rev 2026 Jun;27(6):e70079. PMID 41500509, doi:10.1111/obr.70079.
- Alawadhi AA, Alroudhan D, Alsaeed DJ, et al. "LEAN mass Preservation with Resistance Exercise and Protein during semaglutide and tirzepatide therapy (LEAN-PREP study): a protocol for a randomised controlled trial." BMJ Open 2026 Apr 22;16(4):e116911. PMID 42020128, doi:10.1136/bmjopen-2026-116911.
- ClinicalTrials.gov record NCT06885736 — read 2026-09-21 for status, dates, enrolment and primary outcome.
- Elawa Z, Khalil A, Kardousha A, ElAwwa A, Soliman AT. "GLP-1 receptor agonists and surgical care." Diabetes Res Clin Pract 2026 Jul;237:113332. PMID 42155603, doi:10.1016/j.diabres.2026.113332.
- Capristo E, Panunzi S, De Gaetano A, et al. "Intensive lifestyle modifications with or without liraglutide 3mg vs. sleeve gastrectomy: A three-arm non-randomised, controlled, pilot study." Diabetes Metab 2018 Jun;44(3):235-242. PMID 29398254, doi:10.1016/j.diabet.2017.12.007.